Mineralocorticoid receptor activation and cardiac fibrosis.

Morag J. Young, E. Y. Lam, Amanda J. Rickard

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

MR (mineralocorticoid receptor) activation by either administration of exogenous mineralocorticoids or by allowing endogenous glucocorticoids to activate the MR has been shown to produce oxidative stress and vascular inflammation at the earliest stages of the development of cardiac fibrosis in experimental animals. These studies suggest potential mechanisms for the benefits observed in recent large scale clinical trials investigating the cardioprotective effects of MR antagonists given in conjunction with current best practice therapy for moderate-to-severe heart failure and heart failure post-myocardial infarction. Given that few patients had elevated plasma aldosterone, novel mechanisms involved in activating the MR in the failing heart are now being investigated.

Original languageEnglish
Pages (from-to)467-475
Number of pages9
JournalClinical Science
Volume112
Issue number9
DOIs
Publication statusPublished - Jul 2007
Externally publishedYes

Cite this

Young, Morag J. ; Lam, E. Y. ; Rickard, Amanda J. / Mineralocorticoid receptor activation and cardiac fibrosis. In: Clinical Science. 2007 ; Vol. 112, No. 9. pp. 467-475.
@article{1af8106e076c42bba421438706fd15ef,
title = "Mineralocorticoid receptor activation and cardiac fibrosis.",
abstract = "MR (mineralocorticoid receptor) activation by either administration of exogenous mineralocorticoids or by allowing endogenous glucocorticoids to activate the MR has been shown to produce oxidative stress and vascular inflammation at the earliest stages of the development of cardiac fibrosis in experimental animals. These studies suggest potential mechanisms for the benefits observed in recent large scale clinical trials investigating the cardioprotective effects of MR antagonists given in conjunction with current best practice therapy for moderate-to-severe heart failure and heart failure post-myocardial infarction. Given that few patients had elevated plasma aldosterone, novel mechanisms involved in activating the MR in the failing heart are now being investigated.",
author = "Young, {Morag J.} and Lam, {E. Y.} and Rickard, {Amanda J.}",
year = "2007",
month = "7",
doi = "10.1042/CS20060275",
language = "English",
volume = "112",
pages = "467--475",
journal = "Clinical Science and Molecular Medicine",
issn = "0009-9287",
publisher = "Portland Press",
number = "9",

}

Mineralocorticoid receptor activation and cardiac fibrosis. / Young, Morag J.; Lam, E. Y.; Rickard, Amanda J.

In: Clinical Science, Vol. 112, No. 9, 07.2007, p. 467-475.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Mineralocorticoid receptor activation and cardiac fibrosis.

AU - Young, Morag J.

AU - Lam, E. Y.

AU - Rickard, Amanda J.

PY - 2007/7

Y1 - 2007/7

N2 - MR (mineralocorticoid receptor) activation by either administration of exogenous mineralocorticoids or by allowing endogenous glucocorticoids to activate the MR has been shown to produce oxidative stress and vascular inflammation at the earliest stages of the development of cardiac fibrosis in experimental animals. These studies suggest potential mechanisms for the benefits observed in recent large scale clinical trials investigating the cardioprotective effects of MR antagonists given in conjunction with current best practice therapy for moderate-to-severe heart failure and heart failure post-myocardial infarction. Given that few patients had elevated plasma aldosterone, novel mechanisms involved in activating the MR in the failing heart are now being investigated.

AB - MR (mineralocorticoid receptor) activation by either administration of exogenous mineralocorticoids or by allowing endogenous glucocorticoids to activate the MR has been shown to produce oxidative stress and vascular inflammation at the earliest stages of the development of cardiac fibrosis in experimental animals. These studies suggest potential mechanisms for the benefits observed in recent large scale clinical trials investigating the cardioprotective effects of MR antagonists given in conjunction with current best practice therapy for moderate-to-severe heart failure and heart failure post-myocardial infarction. Given that few patients had elevated plasma aldosterone, novel mechanisms involved in activating the MR in the failing heart are now being investigated.

UR - http://www.scopus.com/inward/record.url?scp=34247891572&partnerID=8YFLogxK

U2 - 10.1042/CS20060275

DO - 10.1042/CS20060275

M3 - Review Article

VL - 112

SP - 467

EP - 475

JO - Clinical Science and Molecular Medicine

JF - Clinical Science and Molecular Medicine

SN - 0009-9287

IS - 9

ER -